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Abstract 
 
 
 
The U.S. Food and Drug Administration (FDA) regulates the promotion of prescription drugs. 
With the emergence of Web 2.0 technology and social media, the FDA faces new regulatory 
challenges as pharmaceutical companies have started to use social media tools to market 
prescription drugs to consumers. This paper first explores the history of social media, its use by 
the FDA, and its growing use by the pharmaceutical industry. The paper then discusses some of 
the actions that the agency has taken to respond to the industry’s use of social media. Lastly, the 
paper takes a look at the FDA’s repeated delays in issuing social media guidance, and discusses 
some of the “social media guidance” that pharmaceutical companies have received from other 
individuals and groups.  
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Introduction 
 
  The use of social media has pervaded and reshaped our society. From Facebook to 
Twitter to LinkedIn, social media websites have provided individuals with newer and faster ways 
to communicate to one another. In 2012, eBizMBA estimated that 700 million unique users 
visited Facebook per month, 200 million users visited Twitter, and 100 million users visited 
LinkedIn.
1 These statistics are staggering. The entire population of the United States, as reported 
by the U.S. Census Bureau, only totals a lofty 312 million.
2  
  With the growing use of social media, many businesses in the U.S. have started to use 
social media as a method of advertising their products to consumers. Large conglomerates such 
as General Electric and Procter & Gamble have incorporated social media into their advertising 
and promotional efforts.
3 Companies including AT&T and Dell use Facebook, Twitter, and 
YouTube to communicate with consumers and market their products.
4 In 2010, Facebook 
boasted that over 1.5 million local businesses had active Facebook pages.
5 
  However, even with these statistics, pharmaceutical companies in the U.S. have taken a 
cautious approach to social media. In 2008, the pharmaceutical industry only allocated a “tiny 
fraction” of “less than 4% of the more than $4 billion it spent on direct-to-consumer advertising” 
                                                         
1 http://www.ebizmba.com/articles/social-networking-websites, last updated Sept. 12, 2011. 
2 http://www.census.gov/main/www/popclock.html, U.S. Census Bureau, last updated Sept. 17, 2011.  
3 W. Glynn Mangold, David J. Faulds, “Social media: The new hybrid element of the promotion mix,” Business 
Horizons, Vol. 52, Issue 4, 358 (2009). 
4 AT&T’s Facebook page, http://www.facebook.com/ATT. AT&T’s Twitter accounts, 
http://twitter.com/#!/ATTNews and http://twitter.com/#!/attblueroom. Listing of Dell’s Twitter accounts, 
http://content.dell.com/us/en/corp/social-media-twitter.aspx. AT&T’s YouTube page, 
http://www.youtube.com/shareatt.  
5 http://www.digitalbuzzblog.com/facebook-statistics-facts-figures-for-2010/, accessed on Jul. 15, 2011.  2 
 
on social media advertising.
6 Unlike advertising in other industries, prescription drug advertising 
is regulated by the U.S. Food and Drug Administration.
7 This means that pharmaceutical 
companies are only allowed to advertise their products under a regulatory scheme that is set up 
by the FDA. Although some venturous pharmaceutical companies have chosen to invest their 
dollars in social media advertising before the FDA gives the industry clear guidance, many have 
been waiting for the FDA to publish a guidance document on social media advertising.  
  In my paper, I plan on addressing the current state of social media use by pharmaceutical 
companies. First, I will give a brief background on social media, its use by the FDA, and its 
growing use by the pharmaceutical industry. Second, I will take a look at what the FDA has 
already done to respond to the use of social media by pharmaceutical companies. And third, I 
will examine the “social media guidance” that the pharmaceutical industry has received from 
other individuals and groups, focusing on Facebook’s recent decision to change its comment 
policy and the impact of this change. I will then conclude.  
Background 
 
What is Social Media? 
 
  Most people agree that we live in a world of social media. But what is “social media” and 
what does it provide its users? Depending on how broadly the term “social media” is defined, its 
roots can be traced back to as early as 1971, when the first email communication was sent.
8  
In their article on social media challenges, Andreas Kaplan and Michael Haenlein define 
social media as a “group of Internet-based applications that build on the ideological and 
technological foundations of Web 2.0, and that allow the creation and exchange of User 
                                                         
6 Jeremy A. Greene, Aaron S. Kesselheim, “Pharmaceutical Marketing and the New Social Media,” N. Engl. J. 
Med., Vol. 363, No. 22, 2087 (2010). 
7 U.S. Food and Drug Administration, “Prescription Drug Advertising: Questions and Answers,” www.fda.gov.  
8 http://mashable.com/2011/01/24/the-history-of-social-media-infographic/, accessed on Jul. 15, 2011.  3 
 
Generated Content.”
9 Web 2.0 roughly came into being in the early 2000s, when online users 
started to use a new generation of web technologies.
10 These new technologies created an online 
platform where content was no longer created and maintained by one user, but where an online 
community of users could continuously make changes to existing content in a collaborative 
fashion.
11 The Internet had become a forum that allowed users to interact and communicate with 
one another using newer and more eclectic forms of content. This content, known as User 
Generated Content (UGC), differed drastically from the content that existed prior to the days of 
Web 2.0, and paved the way for the development of modern day social media.
12  
  Social media today exists in many forms. Blogs, social networking sites, collaborative 
projects, content communities, virtual social worlds, and virtual game worlds can all be classified 
as types of social media applications.
13 The popularity of social media has skyrocketed in the 
past decade. With the introduction of MySpace, Facebook, and other social media sites, a large 
number of businesses and individuals have explored its uses and developed new social media 
tools. Kaplan and Haenlein reported that 75% of Internet users in the second quarter of 2008 
used social media in some shape or form; this represented an increase of nearly 50% from 
2007.
14  
                                                         
9 Andreas M. Kaplan, Michael Haenlein, “Users of the world, unite! The challenges and opportunities of Social 
Media,” Vol. 53, Issue 1, 61 (2010).  
10 Id. at 60-61. The term was first adopted by Tim O'Reilly and Dale Dougherty in 2004, when they used it to 
suggest that a new version of the World Wide Web had replaced the old, Web 1.0. Jack M. Maness , “Library 2.0 
Theory: Web 2.0 and Its Implications for Libraries,” Webology, Vol. 3, No. 2, Art. 25 (2006). 
11 Kaplan, supra note 9. 
12 Id.  
13 Id. at 62. 
14 Id. at 59. 4 
 
  In 2010, the Nielsen Company revealed that the U.S. had the largest number of social 
media users, totaling more than 140 million unique users in December 2009 alone.
15 With the 
large number of users in the U.S., businesses in many industries have started to invest their 
resources in social media. Many businesses have used social media to market their products, 
share and collect information, and promote their public image.
16 In 2008, General Electric and 
Procter & Gamble were able to effectively use social media in their promotional efforts.
17 Their 
success and the success of many other companies demonstrate that social media can indeed be 
used for promotional and marketing purposes.  
  But social media does not merely provide businesses with the opportunity to share 
information with their customers. Its foundations lie in Web 2.0, so it naturally gives consumers 
the opportunity to respond to online promotional material and to communicate their opinions 
with other consumers. Herein lies a danger to businesses. As easy as it is for a business to tell 
millions of individuals about one of its new products, a dissatisfied customer can post spiteful 
comments about the company and discourage these same individuals from purchasing the 
product. To limit the effects of negative publicity, businesses can put in place strong “reputation 
management and social media marketing strategies,”
18 but even with the most robust 
management system in place, admittedly it would still be difficult for a business to monitor the 
online actions of millions of users.  
  With this understanding of social media, I will now address a few of the different types of 
social media in the context of the FDA and the pharmaceutical industry.  
                                                         
15 http://news.cnet.com/8301-1023_3-10457480-93.html, accessed on Jul. 15, 2011.  
16 Mangold, supra note 3, at 357-58.  
17 Id. at 358. 
18 http://www.optimum7.com/internet-marketing/social-media/dangers-of-social-networking-sites.html, accessed on 
Aug. 26, 2011.  5 
 
Use of Social Media by the FDA 
 
  Although some may argue that the FDA’s use of technology is antiquated,
19 the agency 
has adopted and implemented a number of different technology initiatives over the years. In the 
late 1980s, the FDA approved the use of computer-assisted new drug applications (CANDAs) 
which eventually led to the development of the Electronic Regulatory Submission and Review 
(ERSR) Program.
20 This program significantly improved the FDA’s submission and review 
process for new drug applications and still operates as an integral part of the agency today. 
Similarly, in the 1990s, the FDA started using the Internet by running a “highly successful, well-
designed webpage, www.fda.gov, aimed at disseminating information electronically.”
21 This 
webpage continues to provide important information such as regulatory information, guidance 
documents, and health warnings to consumers and businesses.  
  With the development of Web 2.0 and new online technology, the FDA has also 
embraced the use social media sites such as YouTube, Facebook, and Twitter.
22 The agency 
launched its YouTube channel on September 6, 2007, marking its first foray into social media.
23 
YouTube allows its users to upload, share, and view videos online. When adding videos, users 
can include short descriptions of their videos or enable other users to comment on their videos. 
Currently, the FDA uses its YouTube channel as an online tool to “share public health 
                                                         
19 Scott Gottlieb comments that the FDA’s use of technology is antiquated because the agency was unable to 
navigate a company’s recent electronic application. http://www.eyeonfda.com/eye_on_fda/2011/06/fdas-social-
media-assets-twitter-overview.html, accessed on Jul. 2, 2011.  
20 Joel F. Studebaker , “Computers in the New Drug Application Process,” J. Chem. Inf.  Comput. Sci., Vol. 33, No. 
1, 86 (1993); http://www.fda.gov/ohrms/dockets/98fr/980237ss.pdf, accessed on Aug. 17, 2011.  
21 David E. Melaugh, “The Food and Drug Administration and the Internet,” 4 (1999).  
22 http://www.eyeonfda.com/eye_on_fda/2011/09/an-overview-of-fdas-utilization-of-digital-media.html, accessed 
on Sept. 15, 2011.  
23 Id.  6 
 
information with users.”
24 The agency usually posts a short description of each video but does 
not enable commenting on their videos. Some of the FDA’s most recent uploads include a “brief 
video about how to safely choose and use an over-the-counter medicine” and a video on 
“[g]etting kids to eat the fiber they need.”
25 The agency organizes its videos based on subject 
matter and groups videos into different playlists.
26 Since the beginning of September 2011, the 
webpage has been viewed more than 100,000 times and currently has 4,000 YouTube 
subscribers.
27  
  In addition to YouTube, the FDA also uses Facebook to publish information on recalls, 
warning letters, and other agency actions.
28 Facebook is a social networking site that provides 
users with a wide range of services. Users have to first create their own account, but upon 
creating an account, users can use Facebook to communicate with other Facebook users, upload 
pictures and videos, share their interests by “liking” a fan page, and do much more. When users 
“like” a page, updates from that page automatically populate their personal Facebook news 
feeds. Currently, over 14,000 Facebook users have indicated that they “like” the FDA’s 
Facebook fan page. Users like the FDA who create their own fan pages can post information, 
pictures, videos, and links to their pages and invite others to “like” their pages. The FDA has also 
adopted a comments policy that provides clear commenting guidelines and reasons for comment 
                                                         
24 U.S. Food and Drug Administration, “Total number of views of FDA YouTube channel during the month (1),” 
www.fda.gov.  
25 http://www.youtube.com/user/USFoodandDrugAdmin, accessed on Sept. 15, 2011. 
26 Id. 
27 http://www.youtube.com/user/USFoodandDrugAdmin, accessed on Sept. 15, 2011. 
28 http://www.eyeonfda.com/eye_on_fda/2011/09/an-overview-of-fdas-utilization-of-digital-media.html, supra note 
22.  7 
 
removal on its fan page.
29 The enforcement of such a policy is unclear, but as long as Facebook 
users are allowed to remove offensive comments from their fan pages, users would have the 
power to police their own pages.  
  Lastly, the FDA also uses Twitter to microblog about recalls, warning letters, health, 
safety, and a number of other topics and events.
30 Twitter is a social networking site that allows 
users to share short posts of up to 140 characters. The FDA currently has ten Twitter feeds 
including @FDArecalls, @FDA_Drug_Info, and @FDADeviceInfo.
31 The activity and 
following of each “vary greatly.”
32 
  Even though the FDA has successfully navigated the realm of social media, the agency 
can still make improvements. To further optimize its use of social media, the FDA can also use 
Twitter to increase traffic to its Facebook and YouTube pages. The agency can increase its social 
media presence by using additional tools that are available via Twitter and other social media 
sites.  
The Pharmaceutical Industry and Social Media 
 
  Despite the widespread use of social media by the FDA, the agency still has not properly 
advised pharmaceutical companies on the use of social media advertising. Perhaps due to a lack 
of clear guidance, the pharmaceutical industry has mostly refrained from engaging in social 
                                                         
29 http://www.eyeonfda.com/eye_on_fda/2011/09/an-overview-of-fdas-utilization-of-digital-media.html, supra note 
22; http://www.facebook.com/FDA?sk=app_7146470109, accessed on Sept. 15, 2011.  
30 There are ten FDA Twitter feeds. Eye on FDA has “compiled a list that reflects . . . what the FDA is tweeting 
among its various feeds at any given time.” 
30 http://www.eyeonfda.com/eye_on_fda/2011/09/an-overview-of-fdas-
utilization-of-digital-media.html, supra note 22. The list can be accessed at http://twitter.com/#!/list/eyeonfda/fda-
tweets.  
31 http://twitter.com/#!/list/eyeonfda/fda-tweets, supra note 30.  
32 http://www.eyeonfda.com/eye_on_fda/2011/09/an-overview-of-fdas-utilization-of-digital-media.html, supra note 
22.  8 
 
media promotional activities.
33 In their article, “Pharmaceutical Marketing and the New Social 
Media,” Jeremy Greene and Aaron Kesselheim reported that the “drug industry [only] allocated 
[a small fraction of] less than 4% of the more than $4 billion it spent on direct-to-consumers 
advertising” for social networking sites in 2008.
34 Greene and Kesselheim noted that this was 
“surprising” given the large number of consumers who used social media worldwide.
35 However, 
they posited that the reason why many pharmaceuticals companies were hesitant about using 
social media was because they did not know which types of promotional messages would be 
allowed.
36 “To encourage appropriate use of prescription drugs, the FDA has sought to ensure 
that promotional statements make claims about approved indications only and neither overstate 
the benefits nor understate the risks.”
37 But because the agency still has not provided guidance on 
how to strike a “fair balance” between a drug’s risks and benefits in social media advertising, 
pharmaceutical companies have been cautious with their approach to social media.  
  Greene and Kesselheim also noted that pharmaceutical companies in the past “have 
tended to wait for the FDA to establish explicit codes of acceptable marketing practices before 
devoting substantial resources to a new medium.”
38 Many commentators have suggested that 
                                                         
33 See http://news.cnet.com/8301-31921_3-20098572-281/will-the-fda-regulate-social-media-q-a/, accessed on Sept. 
5, 2011 (reporting that PhRMA, a trade association representing pharmaceutical makers, says that pharmaceutical 
companies are still waiting for FDA’s guidance on social media). 
34 Greene, supra note 6.  
35 Id.  
36 Id. at 2087-88. 
37 Id. at 2087. 
38 Examples include direct-to-consumer advertising in print media and prescription drug advertising in broadcast 
media. For both types of advertising, the industry did not invest significant dollars in these new mediums until the 
FDA issued guidance documents. Id. 9 
 
pharmaceutical companies are currently waiting for the FDA to do the same for social media.
39 
However, a few observe that some pharmaceutical companies have started to increase their social 
media spending, and hypothesize that the pharmaceutical industry may increase social media 
spending to “$1.86 billion in 2015.”
40  
  Regardless of whether pharmaceutical spending on social media will increase in the next 
few years, current examples of pharmaceutical companies that have invested significant 
resources in social media include Pfizer, Johnson & Johnson, Novartis, Bayer, Glaxo-Smith-
Kline, and Merck.
41 All of these listed companies currently operate Twitter accounts;
42 a few 
also use other social media sites such as Facebook and YouTube;
43 and a couple have even 
developed their own social media sites such as CML Earth and Think Science Now Blog.
44 
                                                         
39 http://adage.com/article/news/drug-makers-wait-fda-ruling-social-media-dtc-ads/149214/, accessed on May 5, 
2011; http://www.npr.org/blogs/health/2011/08/22/139859210/why-drug-companies-are-shy-about-sharing-on-
facebook, accessed on Sept. 2, 2011; http://www.toprankblog.com/2011/01/social-media-marketing-pharma/, 
accessed on May 5, 2011. 
40 Visible Intelligence, “Is the Return Greater Than the Risk for Pharma Companies Investing in Social Media,” 
2011. See also http://www.marketwatch.com/story/ondine-biomedical-announces-2011-second-quarter-financial-
results-2011-08-10?reflink=MW_news_stmp, accessed on Sept. 5, 2011 (noting that Ondine Biomedical increased 
its marketing and sales expenses for social media purposes).  
41 http://inventorspot.com/articles/top_ten_drug_companies_social_media_31760, accessed on Jul. 6, 2011 (lists the 
top ten drug companies in social media).  
42 Pfizer’s Twitter account, http://twitter.com/#!/Pfizer; Johnson & Johnson’s Twitter account, 
http://twitter.com/#!/JNJComm; Novartis’ Twitter account, http://twitter.com/#!/novartis; Bayer’s Twitter account, 
http://twitter.com/#!/BayerUSNews; Glaxo-Smith-Kline’s Twitter account, http://twitter.com/#!/gsk; Merck’s 
Twitter account, http://twitter.com/#!/MERCK. 
43 Pfizer’s YouTube channel, http://www.youtube.com/PfizerNews; Pfizer’s Facebook page, 
http://www.facebook.com/Pfizer?sk=wall; Johnson & Johnson’s YouTube channel, 
http://www.youtube.com/user/JNJhealth; Glaxo-Smith-Kline’s YouTube channel, 
http://www.youtube.com/user/GSKvision.  
44 CML Earth, https://www.us.cmlearth.com/cmlearth/; Think Science Now Blog, https://science.pfizer.com/.  10 
 
  In his online marketing blog, Dave Folkens encourages more pharmaceutical companies 
to use social media.
45 He argues that it is important for drug companies to build a social media 
presence because “consumers will be talking about [them] whether [they] are [using social 
media] or not.”
 46 Folkens believes that pharmaceutical companies can effectively navigate the 
current regulatory environment by “work[ing] closely with their legal team along with marketing 
professionals with a strong understanding of social media engagements.”
 47 By using these 
resources and others to tap into social media, pharmaceutical companies can revolutionize the 
way they connect with their customers and market their products.  
FDA Guidance on Social Media Advertising 
 
  In the U.S., the FDA regulates prescription drug advertising.
48 This authority passed from 
the Federal Trade Commission (FTC) to the FDA in 1962 when Congress amended the Food, 
Drug, and Cosmetic (FD&C) Act to provide for specific guidelines for prescription drug 
advertising.
49 The FD&C Act does not define the term “advertisements,” but the FDA has 
“interpret[ed] the term to encompass information, other than labeling, that promotes a drug 
product and is sponsored by a manufacturer.”
50 The Act requires that all pharmaceutical 
companies include their drug’s “established name . . ., the formula showing quantitatively each 
                                                         
45 http://www.toprankblog.com/2011/01/social-media-marketing-pharma/, supra note 39.  
46 Id. 
47 Id. Folkens also believes that pharmaceutical companies that “have long applied Direct-to-Consumer (DTC) 
advertising” can use this knowledge to operate in the social media sphere.  He reports that only one out of 52 
warning and notice of violation letters sent to companies in 2010 involved the use of social media. Id. 
48 21 U.S.C. § 352(n). 
49 Peter Barton Hutt, Richard A. Merrill, and Lewis A. Grossman, Food and Drug Law, 3rd ed., 535 (2007). 
50 Francis B. Palumbo, C. Daniel Mullins, “The Development of Direct-to-Consumer Prescription Drug Advertising 
Regulation,” Food and Drug Law Journal, Vol. 57, No. 3, 428 (2002). 11 
 
ingredient of [the] drug . . . , and . . . such other information . . . relating to [the] side effects, 
contraindications, and effectiveness” of the drug in the drug’s advertisements.
51 
To implement its authority, the FDA issued a set of regulations “shortly after . . . the 
1962” amendments to the FD&C Act.
 52 These regulations were later revised in the late 1960s “to 
prohibit specific practices to which the agency had strong objections.”
 53 The regulations impose 
two main requirements on prescription drug manufacturers. First, prescription drug 
advertisements have to include a brief summary of the drug’s “side effects, contraindications, 
and effectiveness.”
54 Second, these advertisements have to present a balanced account of the 
drug that fairly portrays its risks and benefits.
55 This second requirement, commonly known as 
the “fair balance” requirement, is more often cited by the FDA in its warning letters to 
prescription drug advertisers.
56 
  Within the FDA, prescription drug advertising is regulated by the Division of Drug 
Marketing, Advertising, and Communications (DDMAC). The division distinguishes between 
two main types of advertising: advertising that is directed at consumers (i.e., direct-to-consumer 
(DTC) advertising) and advertising that is directed at healthcare professionals. Within DTC 
advertising, the FDA further differentiates between product-claim, reminder, and help-seeking 
advertisements.
57 Product-claim advertisements make claims about a specific product; therefore, 
                                                         
51 21 U.S.C. § 352(n).  
52 Hutt, supra note 49.  
53 Id. 
54 Id. at 539. See also 21 C.F.R. § 202.1(e)(1).  
55 Hutt, supra note 49, at 539. See also 21 C.F.R. § 202.1(e)(5)(ii).  
56 Hutt, supra note 49, at 539.   
57 U.S. Food and Drug Administration, “Regulating Prescription Drug Promotion,” www.fda.gov. 12 
 
these advertisements have to satisfy the brief summary and fair balance requirements.
58 
Reminder advertisements reveal the name of a drug product and may contain certain descriptive 
information but do not discuss the use of a product or make any claims about the product.
59 
These advertisements are also regulated by the FDA.  However, they are exempt from the brief 
summary and fair balance requirements; presumably, the FDA only regulates them to verify that 
they do not make any product claims and are not being used to promote drug products with 
serious warnings known as “black box” warnings.
60 Lastly, help-seeking advertisements do not 
mention any drug product and thus are not regulated by the FDA.
61 
For regulated DTC advertising, DDMAC requires drug companies to present “adequate 
contextual and risk information . . . in understandable language” to consumers that would enable 
them to form an accurate opinion of a drug’s risks and benefits.
62 Pharmaceutical companies are 
not required to obtain preclearance for their advertisements,
63 but they are required to submit all 
of their advertisements to the FDA prior to or at the time they are initially published.
64 
  To ensure regulatory compliance, the FDA also monitors DTC advertisements on a daily 
basis. Third parties such as “concerned citizens, healthcare practitioners, and competitor 
pharmaceutical companies” can also alert the agency about potential violations.
65 If DDMAC 
finds that there has been a violation, it typically issues one of two letters: a Notice of Violation 
                                                         
58 Id. For broadcast product-claim advertisements, because it would be impractical for these advertisements to 
summarize a drug’s risks during the length of the broadcast, companies only need to provide “convenient access to 
the approved labeling.” Id. 
59 Id.  
60 See id. 
61 Id. 
62 Palumbo, supra note 50, at 429. 
63 Except for drugs that were approved under accelerated procedures. 21 C.F.R. § 314.550. 
64 21 C.F.R. § 314.81. 
65 Palumbo, supra note 50, at 429. 13 
 
(NOV) letter for minor violations, or a warning letter for more serious violations. For both NOV 
and warning letters, the division usually asks the identified pharmaceutical company to 
discontinue its violative advertisements and any other advertisements that may also be violative 
for similar reasons. The company is also asked to respond to the FDA within a certain period of 
time, usually spanning ten to fourteen days for NOV letters and fifteen days for warning letters.
66 
For warning letters because they are of a more serious nature, the FDA is also “promis[ing] to 
proceed against the manufacturer if it does not initiate corrective action.” A list of all NOV and 
warning letters to pharmaceutical companies are posted online.
67 
  With the growing use of social media, the FDA and the pharmaceutical industry are faced 
with new challenges involving DTC advertising. Even though many drug companies can use 
social media to market their products in new ways, some are concerned that they cannot satisfy 
the brief summary and fair balance requirements using social media and many others argue that 
they should not have to satisfy the same requirements.
68 Some commentators even argue that 
pharmaceutical companies should not be allowed to promote their products using social media 
tools.
69 In the following sections, I will discuss some of the actions taken by the FDA with 
respect to social media advertising. I will also take a look at the agency’s recent decisions to 
delay issuing guidance on social media.  
                                                         
66 Id.; Office of Inspector General, “FDA Warning Letters: Timeliness and Effectiveness,” 1999, accessed at 
http://oig.hhs.gov/oei/reports/oei-09-97-00381.pdf on Sept. 12, 2011.  
67 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/Warning 
LettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm197224.htm. 
68 Stephen Barlas, “Web of Confusion: FDA Tries to Clarify Rules for Internet Advertising,” Pharmacy and 
Therapeutics, Vol. 35, No. 1, 2010; http://www.nature.com/nbt/journal/v28/n5/full/nbt0510-396.html, accessed on 
Sept. 5, 2011 (noting that “[m]ost of the discussions at the FDA hearings boiled down to the question of whether 
FDA would allow presentations of risk information to differ depending on the media format”). 
69 http://adage.com/article/news/advertising-fda-debate-social-media-dtc-drug-ads/140533/, accessed on Sept. 5, 
2011. 14 
 
NOV and Warning Letters 
 
  The FDA usually issues NOV and warning letters to companies to give them the 
opportunity to voluntarily correct their violations before the agency initiates an enforcement 
measure.
70 In practice, warning letters are only issued for “violations of regulatory significance” 
whereas NOV letters are issues for all other violations that “do not meet the threshold of 
regulatory significance.”
71 Both types of letters are informal and do not commit the FDA to take 
any enforcement action.  
  The agency has only recently begun to issue NOV and warning letters to pharmaceutical 
companies regarding social media advertisements. In 2009, DDMAC issued 14 NOV letters to 
pharmaceutical companies, informing them that their search advertisements – 95-character 
advertisements that ran next to search results – had to start including risk information.
 72 The 
agency made clear that by omitting risk information the companies were publishing false and 
misleading advertisements, which violated federal regulations.
73 But up until issuing these 
letters, the FDA had been vague about whether the same regulatory requirements applied to 
internet search advertisements. And after the agency’s dramatic showing, many commentators 
started to question why the FDA did not develop guidance around new media mediums to help 
pharmaceutical companies navigate these new waters.
74  
                                                         
70 Hutt, supra note 49, at 1339, 1341.  
71 Id. at 1340-41.  
72 http://www.nytimes.com/2009/04/17/business/media/17adco.html?_r=1&scp=1&sq=FDA%20Sows%20 
Confusion&st=cse; accessed on Sept. 5, 2011.  
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  Then in 2010, the number of NOV and warning letters issued by DDMAC increased to 
52.
75 Of the 52, thirteen letters were related to online media including “emails, websites, website 
videos, social media, and/or webcasts.”
76 During the first two quarters of 2011, there have been a 
total of seventeen NOV and warning letters.
77 The majority of these violations dealt with non-
digital media, but one involved a video that was hosted on YouTube.
78  
  In their article, “Roadmap to social media for pharmaceutical companies,” Lauren Tully 
and Lindsey Rozek report that “there appear to be three main problem areas for pharmaceutical 
social media marketing: omission of risk, broadening of indication, and overstatement of 
efficacy.”
79 For the first of these, Tully and Rozek observe that many prescription drug 
advertisements are misleading because “they fail to reveal facts that are material in light of the 
representation made by the materials or with respect to consequences that may result from the 
use of the drug as recommended or suggested by the materials.”
80 For the second, the two 
acknowledge that drug companies are not required to disclose every indication, side effect, and 
contraindications of a drug in their advertisements, but that they have to give a “true statement of 
the effectiveness of the drug for [its advertised] purpose.”
81 Then lastly, for overstatement of 
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efficacy, Tully and Rozek suggest that drug companies should avoid representing that a drug is 
more effective that it has been demonstrated to be in clinical trials or other research studies.
82 
  But despite the growing number of NOV and warning letters that target social media 
advertisements, only one letter to date relates to violations that are uniquely tied to social media. 
Pharmaceutical giant Novartis was using a “Facebook Share” widget in 2010 to market its 
leukemia drug, Tasigna, on individuals’ profile pages and news feeds.
83 The widget posted a 
short description of the drug along with graphics and website links on a Facebook user’s profile 
page and his or her friends’ new feeds if a user indicated that they wanted to “Share” information 
about the drug.
84 The FDA found the shared content to have violated agency regulations because 
the content failed to disclose risk information about the drug, wrongfully indicated that the drug 
applied to all leukemia patients when the drug was only approved for a subset of them, and 
classified the drug as a “next generation” treatment even though there was no clinical data to 
support this contention.
85  
  The Novantis letter demonstrates that the agency is willing to use informal compliance 
measures to regulate social media advertising. However, the restrictions that the letter places on 
Novantis brings to question whether it would even be possible for pharmaceutical companies to 
use social media tools such as the “Facebook Share” widget and Twitter to market their products.  
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Given the space limitations of these tools, it would be difficult for companies to disclose detailed 
risk information about their products to consumers.
86 Consequently, if pharmaceutical companies 
are required to satisfy the same regulatory requirements for social media advertising as they are 
for print advertising, then many of them may be foreclosed from using these types of social 
media tools. But because the FDA still has not issued formal guidance on social media 
advertising, it remains unclear whether social media advertisements are in fact subject to the 
same regulatory standards as other forms of advertisements.  
Hearing on Social Media 
   
On November 12-13, 2009, the agency also held a public hearing to address the growing 
use of social media by pharmaceutical companies and other companies that market FDA-
regulated products (e.g., medical devices, biologics).
87 The FDA acknowledged the “massive 
expansion of new tools and technologies, such as blogs, microblogs, podcasts, social network 
sites . . ., video sharing, widgets, and wikis,” and invited public speakers to comment on issues 
ranging from adverse event reporting to accountability and transparency.
88  
  Among the questions asked by the FDA was: how should companies present information 
about their products using social media tools “to ensure that user[s] ha[ve] access to a balanced 
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presentation of both risks and benefits of medical products.”
89 Recall that the agency’s 
regulations require prescription drug advertisements to contain a brief summary of the drug’s 
side effects, contraindications, and effectiveness.
 90 These regulations also require drug 
advertisements to present a fair balance between information relating to the risks and benefits of 
the drug.
91 Furthermore, in order to be truthful and nonmisleading, “risk information [about the 
drug] must be presented with a prominence and readability reasonably comparable to claims 
about [the] drug’s benefits.”
92 All pharmaceutical companies are also “responsible for submitting 
copies of promotional materials to [the] FDA.”
93 
During the public hearing, Tony Blank speaking on behalf of AdvaMed argued that the 
FDA needs to take into account the various aspects of social media (e.g., type of medium, space 
limitations) when it develops guidelines for the biomedical and pharmaceutical industries.
94 
Many other speakers expressed similar viewpoints, proposing that the FDA needs to adopt 
guidance measures that are Internet-specific and take into account the limitations and advances 
of social media technology.
95 Rohit Barghava and several other speakers supported adopting a 
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one-click rule where consumers could gain access to important safety information about a 
product by clicking on a link in its social media advertisement.
96 Barghava argued that due to 
space limitations on social media sites such as Twitter, it is difficult for many companies to 
include enough information in their advertisements to satisfy regulatory requirements.
97 
Therefore, the one-click rule presents an effective solution to this problem because it not only 
provides consumers with access to a product’s important information but also allows 
pharmaceutical companies to continue advertising their products via Twitter and other social 
media tools. Philomena McArthur, Senior Director of Regulatory Affairs at Johnson & Johnson, 
also suggested that “rollover and scrolling functions can enable direct connections to safety and 
efficacy information” when using social media tools with space limitations.
98   
Representatives from Yahoo! and Google also presented information on new social 
media tools that they were developing to help pharmaceutical companies advertise their products 
in ways that comply with regulatory requirements.
99 In addition to talking about the differences 
between social media and other existing forms of media (e.g., print, TV), Yahoo! Vice President 
Dave Zinman also talked about the different expectations that individuals have when they look at 
content online versus watching it on TV. For example, he explained that most “people don’t have 
the attention span” to watch longer broadcast-compliant videos online because they “don’t have 
to wait” or at least do not expect to wait “for [a] video to finish to get to the content [they 
want].”
100 Therefore, to remedy this problem, he suggested that pharmaceutical companies 
should be allowed to run shorter video advertisements coupled with important safety information 
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about a drug that is shown at the same time the video is shown.
101 Consumers viewing these 
videos can then take as long as they want to look over the drug’s important safety information 
and to click on links that would reveal more product and safety information.  
   However, some speakers also expressed concerns about the growing use of social media 
by the pharmaceutical and medical device industries. Steven Findlay representing the Consumers 
Union argued that the FDA should prevent companies from “layering” information about their 
products in a way that would bury important risk and safety information.
102 He opined that 
companies should not be allowed to advertise only “good stuff” about their products to 
consumers and to require them to click-through to any critical side effect information.
103 
Displaying product information in this way would mislead consumers into believing that a drug 
is more safe and effective than it is. Findlay also suggested that prescription drug and medical 
device companies should not be allowed to use space-limited mediums to advertise their 
products directly to consumers (e.g., text messaging, social networking bulletin boards).
104 He 
recommends that the best and most legitimate way for companies to use social media tools to 
communicate with consumers is through their company websites.
105  
  Ben Wolin, speaking from the other side, supported the adoption of a one-click rule but 
expressed doubts about using other browsing features (e.g., scrolling) because oftentimes the 
“text gets so minimized . . . [that] you can’t find it . . . [and] it’s really not achieving what 
[companies and the FDA] want it to achieve.”
106 Allan Coukell, the Director of the Pew 
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Prescription Project, also voiced his concerns about using space-limited platforms. Coukell 
argued that social media advertisements should be held to the same regulatory standards as other 
types of media promotion because “space is essentially unlimited [on the Internet], unlike TV 
and broadcast media.”
107 Consequently, Twitter and other social media tools with space 
limitations should not be used if they do not allow companies to effectively communicate 
important risk and safety information about their products to consumers. But before the agency 
should issue any guidance on the use of social media tools with space limitations, Coukell also 
advised the FDA to conduct studies on consumer comprehension of risk information presented in 
“various abbreviated forms.”
108  
  In addition to addressing regulatory concerns for social media, speakers at the hearing 
also talked several other issues including: what communications are pharmaceutical and medical 
device companies accountable for online, “what parameters should apply to the posting of 
corrective information” online, and when is it appropriate to use links. In general, speakers 
agreed that companies should strive to be transparent with respect to their influence and control 
over content but should not be responsible for monitoring and policing the Internet.
109 Presenters 
supported having clear linking and posting policies on company-controlled websites and utilizing 
links and other tools that would give online users the opportunity to report misuse.
110 And most 
parties agreed that companies should adhere to present best practices until the FDA issues formal 
guidance on the use of social media. 
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Delay in Social Media Guidance 
 
Following the November hearing, the FDA initially announced that it would issue 
guidance on social media by the end of 2010.
111 Jean-Ah Kang, Special Assistant to DDMAC 
Director Tom Abrams, told Medical Marketing & Media that the agency was on track to at least 
issue partial guidance on some of the issues raised by the FDA and addressed by speakers during 
the hearing.
112 As the 2010 year came to an end however the agency announced that it would not 
be issuing guidance on social media until the first quarter of 2011.
113 In its email to Eye on FDA, 
DDMAC stated that the agency’s new goal was to issue a guidance document during the first 
quarter of 2011 that addressed one of several important issues.
114 Key among these issues was 
“[r]esponding to unsolicited requests,” a topic that was not raised by the FDA during the 
November hearing and was only briefly discussed by one of the speakers.
115 But this new issue 
may be one that concerned many pharmaceutical companies because they are exposed to 
unsolicited requests via social media sites such as Facebook, Twitter, and YouTube on a daily 
basis.
116  
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However, during the first quarter of 2011, DDMAC Director Abrams attended the Drug 
Information Association’s (DIA) annual marketing meeting and announced that “industry and 
agencies should not expect major changes in social media marketing rules.”
117 After being asked 
about advice that he would give to companies regarding the use of social media, Abrams replied 
that companies should continue to “follow existing regulations and policies” because he does not 
expect the agency’s guidance to include any “new regulations or new standards” for social 
media.
118 Abrams suggested that the agency would still be issuing industry guidelines by April, 
but as we quickly approach the final months of the 2011 year, it is clear that the agency no longer 
has plans to issue social media guidelines by the end of the year.
119  
Many individuals and companies have expressed frustration at the FDA’s decision to 
delay social media guidance yet again.
120 In his blog on the FDA, Jeffrey Wasserstein jokingly 
comments that the FDA may not need to bother with issuing guidance when it has NOV letters 
and other enforcement measures at its disposal.
121 The Public Relations Society of America 
recognizes that the agency has been assigned a difficult task, but still urges the FDA to quickly 
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adopt guidelines so that patient communities and pharmaceutical companies can benefit more 
readily from the use of social media.
122  
Other “Social Media Guidance” 
 
  Even though the FDA has not issued formal guidance on social media advertising, 
pharmaceutical companies have started to publish their own social media guidelines. In 2010, 
Roche distributed a guidance letter to employees that encouraged them to “approach online 
worlds in the same way [they] do the physical one – by using sound judgment and common 
sense.”
123 Pfizer Canada posted a flow chart online that instructs pharmaceutical companies on 
how to response to social media communications.
124 And AstraZeneca, in December 2010, 
published a white paper that “outlin[es] its guidelines for social media use by the pharmaceutical 
industry.”
125  
Recently, in May 2011, Dr. Bertalan Mesko launched the Open Access Social Media 
Guide for Pharma (Open Access Guide), which is an online guide that provides pharmaceutical 
companies, medical professionals, and patients with information on social media use.
126 Most 
notably, the Open Access Guide delivers guidance to pharmaceutical companies on how to use 
Facebook, Twitter, Wikipedia, and other social media tools.
127 For using Facebook, the Open 
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Access Guide recommends that companies should communicate regularly with users, clearly 
define their moderation policy for removing comments, and closely monitor their fan page 
walls.
128 The guide also includes links to negative and positive examples of pharmaceutical 
companies using Facebook.
129  
  On August 15, 2011, Facebook also issued its own “social media guidance” for 
pharmaceutical companies.
130 The company had emailed its pharmaceutical clients back in May, 
informing them about its upcoming policy change.
131 Facebook’s new comment policy required 
drug companies to allow other Facebook users to comment on their fan page walls. The social 
media giant explained that this change would encourage more two-way dialogue between 
companies and people on Facebook, which has always been one of the company’s foremost 
objectives.
132  
Pharmaceutical companies have responded differently to Facebook’s policy change. 
Some companies such as AstraZeneca and Johnson & Johnson have closed their fan pages.
133 
Others have announced that they are redesigning their Facebook pages to comply with its new 
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comment policy.
134 Still some have chosen to stay with Facebook and opened up their walls to 
public comments; conceivably, these companies have also ramped up their moderation efforts.
135  
  The impact that Facebook’s policy change had on pharmaceutical companies 
demonstrates how much influence Facebook and other social media sites have over the social 
media advertising. Many companies are concerned that allowing public commenting would lead 
to unsolicited requests and other undesirable statements. In its legal blog, Fuerst Ittleman notes 
that the public can now “comment about adverse side effects, promote off-label uses, or make 
inappropriate statements about pharmaceutical products.”
136 Because drug companies fear that 
these comments could tarnish their brand image or force them to file adverse event reports with 
the FDA, many of them have moved away from using Facebook.  
  Justin Goldsborough comments in his blog that Facebook’s recent decision to allow 
public comments on drug company pages has given the FDA another reason to “sit on its 
collective hands and adopt a ‘wait and see’ mentality without taking a true stand on how drug 
companies can or can’t communicate with customers via social.”
137 He predicts that Facebook’s 
policy change “won’t be that big of a deal” because the pharmaceutical industry will quickly 
learn how to use Facebook pages like other industries do today.
138 But an important distinction 
separates pharmaceutical companies from these other companies: the FDA’s regulatory 
involvement. Therefore, it remains unclear whether Facebook’s “social media guidance” will 
make it difficult for the pharmaceutical industry to fully embrace social media in the long-run.   
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Conclusion 
   
As discussed in this paper, pharmaceutical companies have struggled with the use of 
social media during the past few years. The FDA continues to use enforcement measures such as 
NOV and warning letters to regulate social media content, while remaining silent about social 
media guidelines. Meanwhile, Facebook has decided to take matters into its own hands by 
delivering its own dose of “social media guidance.” As more pharmaceutical companies shy 
away from using social media, some commentators have started to consider whether it is time to 
give up on social media advertising for prescription drugs.
139 
  In her article, “FDA’s Policy on Social Media,” Kristi Wolff identifies one of the key 
risks associated with using social media: the risk of losing control over one’s content.
140 She 
encourages companies to overcome this risk though by “be[ing] proactive and determin[ing] up 
front how to handle scenarios in which consumer generated content may create legal risk.”
141 
Greene and Kesselheim also point out that many pharmaceutical companies are concerned that 
they will not be able to satisfy regulatory requirements “in the dynamic and expanding matrix of 
networked media.”
 142 But with the development of resources such as the Open Access Guide, 
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these companies should be able to overcome this concern by following best practices and 
learning from others’ experiences. 
  In conclusion, even though the FDA has not issued clear guidance on the use of social 
media, pharmaceutical companies should continue to explore this evolving area of technology. 
Social media has become an integral part of our society, and the pharmaceutical industry may 
have to learn how to use it sooner or later.  